Samuel Charles Blackman

Title: Samuel Charles Blackman: Innovator in CAR T-Cell Therapy

Introduction

Samuel Charles Blackman is a notable inventor based in Seattle, WA (US). He has made significant contributions to the field of cell therapy, particularly in the area of CAR T-cell therapy. His innovative work focuses on improving the safety and efficacy of therapeutic T cell compositions.

Latest Patents

Samuel Blackman holds a patent for "Determining toxicity risk in CAR T-cell therapy." This patent outlines methods, compositions, and articles of manufacture for use in connection with cell therapy involving the administration of therapeutic T cell compositions. The T cell compositions express recombinant receptors, such as chimeric antigen receptors (CARs) or other transgenic receptors. The features of this invention, including the number of cells administered and the potency of those cells, provide advantages such as a lower risk of toxicity in subjects receiving the T cell compositions. He has 1 patent to his name.

Career Highlights

Samuel Blackman is currently associated with Juno Therapeutics GmbH, where he continues to advance research in cell therapy. His work is pivotal in developing safer therapeutic options for patients undergoing CAR T-cell therapy.

Collaborations

Samuel collaborates with esteemed colleagues, including Brian Christin and Michael Gerard Covington, who contribute to the innovative research environment at Juno Therapeutics GmbH.

Conclusion

Samuel Charles Blackman is a key figure in the advancement of CAR T-cell therapy, with a focus on reducing toxicity risks in patients. His contributions are vital to the ongoing development of safer and more effective cell therapies.